Success Metrics

Clinical Success Rate

40.0%

Based on 2 completed trials

Completion Rate

40%(2/5)

Active Trials

0(0%)

Results Posted

150%(3 trials)

Terminated

3(60%)

Phase Distribution

Ph phase_2

80%

Ph phase_3

20%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution5 total trials

Phase 2Efficacy & side effects

4(80.0%)

Phase 3Large-scale testing

1(20.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

40.0%

2 of 5 finished

Non-Completion Rate

60.0%

3 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Completed(2)

Terminated(3)

Detailed Status

Terminated3

Completed2

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

40.0%

Most Advanced

Phase 3

Trials by Phase

Phase 24 (80.0%)

Phase 31 (20.0%)

Trials by Status

terminated360%

completed240%

Recent Activity

0 active trials

Showing 5 of 5

terminatedphase_3

Phase 2b Pivotal Study of Izokibep in Non-infectious, Intermediate-, Posterior- or Pan-uveitis

NCT05384249

completedphase_2

A Trial of the Efficacy and Safety of Izokibep in the Treatment of Non-anterior Uveitis

NCT04706741

Clinical Trials (5)

Showing 5 of 5 trials

NCT05905783Phase 3

Hidradenitis Suppurativa Study of Izokibep

Terminated

NCT05355805Phase 2

Hidradenitis Suppurativa Phase 2b Study of Izokibep

Completed

NCT05623345Phase 2

Psoriatic Arthritis Study of Izokibep

Terminated

NCT05384249Phase 2

Phase 2b Pivotal Study of Izokibep in Non-infectious, Intermediate-, Posterior- or Pan-uveitis

Terminated

NCT04706741Phase 2

A Trial of the Efficacy and Safety of Izokibep in the Treatment of Non-anterior Uveitis

Completed

All 5 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 5